Rispens T - Search Results

1

IgG4 production against adalimumab during long term treatment of RA patients.

van Schouwenburg PA, Krieckaert CL, Nurmohamed M, Hart M, Rispens T, Aarden L, Wouters D, Wolbink GJ. van Schouwenburg PA, et al. Among authors: rispens t. J Clin Immunol. 2012 Oct;32(5):1000-6. doi: 10.1007/s10875-012-9705-0. Epub 2012 May 24. J Clin Immunol. 2012. PMID: 22622790

2

Immunoglobulin G4: an odd antibody.

Aalberse RC, Stapel SO, Schuurman J, Rispens T. Aalberse RC, et al. Among authors: rispens t. Clin Exp Allergy. 2009 Apr;39(4):469-77. doi: 10.1111/j.1365-2222.2009.03207.x. Epub 2009 Feb 13. Clin Exp Allergy. 2009. PMID: 19222496 Review.

3

Human IgG4 binds to IgG4 and conformationally altered IgG1 via Fc-Fc interactions.

Rispens T, Ooievaar-De Heer P, Vermeulen E, Schuurman J, van der Neut Kolfschoten M, Aalberse RC. Rispens T, et al. J Immunol. 2009 Apr 1;182(7):4275-81. doi: 10.4049/jimmunol.0804338. J Immunol. 2009. PMID: 19299726 Free article.

4

Traces of pFc' in IVIG interact with human IgG Fc domains and counteract aggregation.

Rispens T, Himly M, Ooievaar-De Heer P, den Bleker TH, Aalberse RC. Rispens T, et al. Eur J Pharm Sci. 2010 Apr 16;40(1):62-8. doi: 10.1016/j.ejps.2010.03.001. Epub 2010 Mar 6. Eur J Pharm Sci. 2010. PMID: 20211252

5

Label-free assessment of high-affinity antibody-antigen binding constants. Comparison of bioassay, SPR, and PEIA-ellipsometry.

Rispens T, Te Velthuis H, Hemker P, Speijer H, Hermens W, Aarden L. Rispens T, et al. J Immunol Methods. 2011 Feb 28;365(1-2):50-7. doi: 10.1016/j.jim.2010.11.010. Epub 2010 Nov 27. J Immunol Methods. 2011. PMID: 21115013

6

Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody.

Rispens T, Leeuwen Av, Vennegoor A, Killestein J, Aalberse RC, Wolbink GJ, Aarden LA. Rispens T, et al. Anal Biochem. 2011 Apr 15;411(2):271-6. doi: 10.1016/j.ab.2011.01.001. Epub 2011 Jan 7. Anal Biochem. 2011. PMID: 21216215

7

Differential effect of drug interference in immunogenicity assays.

Hart MH, de Vrieze H, Wouters D, Wolbink GJ, Killestein J, de Groot ER, Aarden LA, Rispens T. Hart MH, et al. Among authors: rispens t. J Immunol Methods. 2011 Sep 30;372(1-2):196-203. doi: 10.1016/j.jim.2011.07.019. Epub 2011 Jul 29. J Immunol Methods. 2011. PMID: 21824477

8

Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing.

Rispens T, de Vrieze H, de Groot E, Wouters D, Stapel S, Wolbink GJ, Aarden LA. Rispens T, et al. J Immunol Methods. 2012 Jan 31;375(1-2):93-9. doi: 10.1016/j.jim.2011.09.011. Epub 2011 Oct 1. J Immunol Methods. 2012. PMID: 21986105

9

Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped.

Rispens T, Vennegoor A, Wolbink GJ, Polman CH, Killestein J. Rispens T, et al. Mult Scler. 2012 Jun;18(6):899-901. doi: 10.1177/1352458511431073. Epub 2011 Dec 19. Mult Scler. 2012. PMID: 22183929

10

Immunogenicity of biological therapeutics: from assay to patient.

Krieckaert C, Rispens T, Wolbink G. Krieckaert C, et al. Among authors: rispens t. Curr Opin Rheumatol. 2012 May;24(3):306-11. doi: 10.1097/BOR.0b013e3283521c4e. Curr Opin Rheumatol. 2012. PMID: 22388644 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

302 results

Search Page

Filters